The combination between pimasertib, a MEK1/2 inhibitor, and voxtalisib, a dual PI3K/mTOR inhibitor among patients affected by solid tumors, including melanoma, was tested in a phase Ib trial in 146 patients. This evidence concerns the gene MTOR and melanoma.